Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage

Prostate Cancer and Prostatic Diseases
Catherine Handy MarshallEmmanuel S Antonarakis

Abstract

DNA repair gene mutations are present in 8-10% of localized prostate cancers. It is unknown whether this is influenced by clinicopathologic factors. We interrogated localized prostate adenocarcinomas with tumor DNA sequencing information from the TCGA validated (n = 333) and Nature Genetics (n = 377) datasets. Homologous recombination repair genes included in our analysis were: ATM, BRCA1/2, CDK12, CHEK1/2, FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, and RAD51C. Proportions of cases with pathogenic DNA repair mutations (and in ATM/BRCA1/2 specifically) were reported by Gleason grade group, clinical T, pathologic T, and pathologic N stage. Odds ratios and Fisher's exact tests were used to compare proportions between categories. Patients with Gleason grade groups 3 and higher were 2.2 times more likely to harbor any DNA repair mutation (95% CI: 1.2-4.2; 10.3% versus 5.0%) and were 2.7 times more likely to have BRCA1/2 or ATM mutations (95% CI: 1.3-6.6; 7.0% versus 2.7%) compared to those in Gleason grade groups 1-2. Patients with pathologic T3 and T4 stage (pT3/pT4) were 2.6 times more likely to have any DNA repair mutation (95% CI: 1.3-6.6; 13.0% versus 5.5%) and were 3.2 times more likely to have BRCA1/2 or ATM mutations (95...Continue Reading

References

Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus GraefenMichael W Kattan
Jun 15, 2007·Journal of the National Cancer Institute·Laufey TryggvadóttirHrafn Tulinius
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elena CastroRosalind Eeles
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bella KaufmanSusan M Domchek
May 23, 2015·Cell·Dan RobinsonArul M Chinnaiyan
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Nov 7, 2015·Cell·UNKNOWN Cancer Genome Atlas Research Network
Jan 10, 2017·Nature·Michael FraserPaul C Boutros
Jun 3, 2017·Expert Review of Clinical Pharmacology·Benjamin A Teply, Emmanuel S Antonarakis
Dec 14, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Veda N GiriLeonard G Gomella
Apr 4, 2018·Nature Genetics·Joshua ArmeniaEliezer M Van Allen
Nov 30, 2018·Nature Reviews. Cancer·Michelle Trenkmann

❮ Previous
Next ❯

Citations

Mar 14, 2020·Current Opinion in Oncology·Catherine H Marshall, Emmanuel S Antonarakis
Nov 15, 2018·Frontiers in Oncology·Francesca GiunchiMichelangelo Fiorentino
Dec 25, 2019·The Journal of Clinical Investigation·Joaquin MateoJohann S de Bono
Feb 15, 2020·Nature Communications·Scott WilkinsonAdam G Sowalsky
Jul 20, 2019·International Journal of Oncology·Shona H LangRuben G W Quek
Oct 28, 2020·Technology in Cancer Research & Treatment·Eda G Ramirez-VallesCarlos A Alba-Fierro
Nov 24, 2020·Expert Review of Anticancer Therapy·Lisa MorisSteven Joniau
Jul 23, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Harsimar KaurTamara L Lotan
Jan 5, 2021·La Radiologia medica·Antonella SantoneLuca Brunese
Dec 2, 2020·The Prostate·Mary H BlackJianfeng Xu
Jun 11, 2020·Trends in Cancer·Susanne Burdak-RothkammKai Rothkamm
Apr 9, 2021·Expert Opinion on Pharmacotherapy·Benjamin L Maughan, Emmanuel S Antonarakis
Oct 12, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Clemens KratochwilAlbrecht Stenzinger
Aug 12, 2021·OncoTargets and Therapy·Zhenwei WangZhiyu Liu
Aug 11, 2021·Surgical Pathology Clinics·Ibrahim KulacMichael C Haffner
Sep 17, 2021·Nature Reviews. Urology·Gaëtan DevosSteven Joniau

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Clinical Trials Mentioned

NCT03040791
NCT03442556
NCT03012321
NCT02952534
NCT02975934
NCT02854436

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.